ReviewJACC. CardioOncology2024
Cancer Therapy and Exercise Intolerance: The Heart Is But a Part:
Review in JACC. CardioOncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Endothelial Injury as a Potential Contributor to Cardiovascular Toxicity in Hematologic Malignancies.Diseases (Basel, Switzerland) · 2026Review
- Resistance Exercise: A Potential Intervention for Managing Cardiovascular Health in Individuals with a History of Cancer.Sports medicine - open · 2026Article
- Sympathetic Neural Overactivation, Vascular Dysfunction, and Exercise Intolerance in Long-Term Survivors of Breast Cancer Treated With Doxorubicin and Trastuzumab-Based Chemotherapy.Journal of the American Heart Association · 2026Article
- Microvascular skeletal muscle oxygenation and exercise capacity in childhood cancer survivors compared to healthy controls: a cross-sectional study.Scientific reports · 2025Article
- New insights into total and resting energy expenditure using state-of-the-art methods in cancer survivors: a cross-sectional study.The American journal of clinical nutrition · 2025Article
- Impact of Chemotherapy on Motor-Cognitive Dual-Task Performance in Strength and Mobility Tests.Healthcare (Basel, Switzerland) · 2025Article
- Handgrip strength assessment in breast cancer patients: validity and reliability of the Activ5 dynamometer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Cardio-oncology rehabilitation and exercise: evidence, priorities, and research standards from the ICOS-CORE working group.European heart journal · 2025Review
- Effects of Aerobic Exercise on Cardiorespiratory Fitness and Cardiovascular Risk Factors in Long-Term Breast Cancer Survivors: A Randomized Controlled Trial.JACC. CardioOncology · 2025Article
- Exercise Prescription in Cardio-Oncology.Journal of clinical medicine · 2025Review
- Impaired Cardiorespiratory Fitness in Cancer Survivors: Time to Come Together to Solve a Complex Problem.JACC. CardioOncology · 2025Article
- Effects of Systemic Anticancer Treatment on Cardiorespiratory Fitness: A Systematic Review and Meta-Analysis.JACC. CardioOncology · 2025Article
- Distinct Impact of Doxorubicin on Skeletal Muscle and Fat Metabolism in Mice: Without Dexrazoxane Effect.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The landscape of cancer therapeutics is continually evolving, with successes in improved survivorship and reduced disease progression for many patients with cancer. Improved cancer outcomes expose competing comorbidities, some of which may be exacerbated by cancer therapies. The leading cause of disability and death for many early-stage cancers is cardiovascular disease (CVD), which is often attributed to direct or indirect cardiac injury from cancer therapy. In this review, the authors propose that toxicities related to conventional and novel cancer therapeutics should be considered beyond the heart. The authors provide a framework using the oxygen pathway to understand the impact of cancer treatment on peak oxygen uptake, a marker of integrative cardiopulmonary function and CVD risk. Peripheral toxicities and the impact on oxygen transport are discussed. Consideration for the broad effects of cancer therapies will improve the prediction and identification of cancer survivors at risk for CVD, functional disability, and premature mortality and those who would benefit from therapeutic intervention, ultimately improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.